Skip to main content

Profiles

David Boulware

David Boulware

David R. Boulware is an American infectious diseases researcher based in Minnesota. He is a professor and physician at the University of Minnesota Medical School and faculty member at the University of Minnesota School of Public Health.[1]

History

Boulware graduated from Wabash College in 1996 with a Bachelor of Arts in Chemistry.[2] He was a member of the Phi Kappa Psi fraternity.[3]

He later attended the Indiana University School of Medicine, graduating in 2000.[4] He completed various residencies and fellowships from 2000-2007, receiving a certificate in tropical medicine from the Centers for Disease Control and Prevention (CDC) in 2006. He completed his Masters in Public Health in 2007.

Career

Boulware joined the faculty of the University of Minnesota in 2007. He was named to the Lois and Richard King Distinguished Assistant Professorship at UMN in 2011.[2:1]

Since 2006, Boulware has conducted research through a collaboration between the University of Minnesota and Uganda Hub.[4:1] He has studied cryptococcal meningitis, as well as HIV immune reconstitution inflammatory syndrome (IRIS) at the Center for Infectious Diseases and Microbiology Translational Research (CIDMTR) in collaboration with researchers at the Infectious Diseases Institute (IDI) in Kampala, Uganda.[5] His early efforts were funded by the University of Minnesota's Academic Health Center, Tibotec (which later merged with Janssen) and the National Institutes of Health (NIH).[6]

One of Boulware's HIV studies at the IDI, published in December 2017, was featured in the Joint United Nations Programme on HIV/AIDS (UNAIDS)' August 2018 report titled “Miles to Go.”[7][8][9]

COVID-19

Boulware served as principal investigator in the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19, which began on March 17, 2020.[10] The study, titled “Post-exposure Prophylaxis or Preemptive Treatment for SARS-Coronavirus-2,” was funded by Jan and David Baszucki, Steve Kirsch, University of Minnesota Foundation, the Alliance of Minnesota Chinese Organizations and Minnesota Chinese Chamber of Commerce.[11] Further funding for the Canadian arms of the trial came from:[12]

  • Bridge to Health Medical and Dental
  • Manitoba Medical Service Foundation
  • McGill Interdisciplinary Initiative in Infection and Immunity (MI4)
  • McGill University Health Centre (MUHC)
  • Northern Alberta Clinical Trials and Research Centre
  • Research Institute of St. Joe's Hamilton
  • St. Joseph's Hospital Foundation

Collaborators and trial sites included the University of Minnesota, University of Alberta, University of Manitoba and the Research Institute of the McGill University Health Centre.[13] The hydroxychloroquine for the trial was donated by Rising Pharmaceuticals in the United States and Apotex in Canada.[14]

On June 3, 2020, the results of Boulware's trial were published in the New England Journal of Medicine (NEJM), finding that “hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.”[15]

Later in June, Boulware provided commentary to the press about the price of remdesivir, saying that “from the health system perspective, if remdesivir can shorten duration of hospitalization by four days, then the medicine provides a reasonable value.”[16]

Research

Boulware's areas of research and clinical trials include cryptococcus, HIV, meningitis, sertraline and tuberculosis.

He has received research funding from:[17]

He has additionally acted as an advisor to Viamet Pharmaceuticals and Minnetronix.[18:1]

  1. David R Boulware. Experts@Minnesota. Retrieved May 26, 2022, from https://web.archive.org/web/20220526151302/https://experts.umn.edu/en/persons/david-r-boulware ↩︎

  2. Dr. David Boulware ’96/King Distinguished Professor at UMN – Alumni News. (2011, November 4). Wabash College. http://archive.today/2023.05.17-050444/https://blog.wabash.edu/alumninews/2011/11/04/dr-david-boulware-96king-distinguished-professor-at-umn/ ↩︎ ↩︎

  3. Paige, R. (2020, April 2). With a Gift for Science, Boulware ’96 Seeks Cure. Wabash College. http://archive.today/2023.05.17-233333/https://www.wabash.edu/news/story/11580 ↩︎

  4. Boulware, D. R. (2021). Clinical & Translational Research in Cryptococcosis. Mycoses Study Group Education & Research Consortium. https://web.archive.org/web/20230517231334/https://msgerc.org/resources/Documents/Boulware Slides_4.26.pdf ↩︎ ↩︎

  5. David R. Boulware, M.D., MPH, DTM&H; - MED - DOM - Infect Diseases Microbiol Trans Research, University of Minnesota. Center for Infectious Diseases and Microbiology Translational Research. Retrieved June 21, 2010, from https://web.archive.org/web/20100621123616/http://www.cidmtr.umn.edu/investigators/boulware/home.html ↩︎

  6. Schmickle, S. (2008, November 13). University of Minnesota doctors battle AIDS in Uganda. MinnPost. http://archive.today/2010.06.23-113510/http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda ↩︎

  7. UNAIDS. (2018). Miles to Go—closing gaps, breaking barriers, righting injustices (p. 103). Joint United Nations Programme on HIV/AIDS. https://web.archive.org/web/20230508052828/https://www.unaids.org/sites/default/files/media_asset/miles-to-go_en.pdf ↩︎

  8. Flynn, A., Godwin Anguzu, Mubiru, F., Kiragga, A., Kamya, M. R., Meya, D. B., Boulware, D. R., Kambugu, A., & Castelnuovo, B. (2017). Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy. PLOS ONE, 12(12), e0189055–e0189055. https://doi.org/10.1371/journal.pone.0189055 ↩︎

  9. IDI research manuscript cited in UNAIDS 2018 global report. Infectious Diseases Institute. Retrieved December 8, 2022, from https://web.archive.org/web/20221208223013/https://idi.mak.ac.ug/idi-research-manuscript/ ↩︎

  10. Home | Post-exposure Prophylaxis or Preemptive Treatment for Coronavirus. (2020, June 3). University of Minnesota. http://archive.today/2020.07.18-030252/https://covidpep.umn.edu/ ↩︎

  11. Support | Post-exposure Prophylaxis or Preemptive Treatment for Coronavirus. University of Minnesota. Retrieved December 11, 2022, from http://archive.today/2022.12.11-173505/https://covidpep.umn.edu/support ↩︎

  12. Lofgren, S. M., Nicol, M. R., Bangdiwala, A. S., Pastick, K. A., Okafor, E. C., Skipper, C. P., Pullen, M. F., Engen, N., Abassi, M., Williams, D. A., Nascene, A. A., Axelrod, M. L., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Cheng, M. P., Zarychanshi, R., Schwartz, I. S., & Silverman, M. J. (2020). Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. medRxiv. https://doi.org/10.1101/2020.07.16.20155531 ↩︎

  13. University of Minnesota, McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Manitoba, & University of Alberta. (2021, May 13). Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial. ClinicalTrials.gov. https://web.archive.org/web/20230513212649/https://www.clinicaltrials.gov/ct2/show/NCT04308668 ↩︎

  14. Boulware, D. (2020). ICMJE Form for Disclosure of Potential Conflicts of Interest. New England Journal of Medicine (pp. 8–9). https://web.archive.org/web/20230516161717/https://www.nejm.org/doi/suppl/10.1056/NEJMoa2016638/suppl_file/nejmoa2016638_disclosures.pdf ↩︎

  15. Boulware, D. R., Pullen, M. F., Bangdiwala, A. S., Pastick, K. A., Lofgren, S. M., Okafor, E. C., Skipper, C. P., Nascene, A. A., Nicol, M. R., Abassi, M., Engen, N. W., Cheng, M. P., LaBar, D., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Zarychanski, R., Kelly, L. E., & Schwartz, I. S. (2020). A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 383(6). https://doi.org/10.1056/nejmoa2016638 ↩︎

  16. Drug company to charge thousands for coronavirus treatment. (2020, June 29). NBC News; Associated Press. http://archive.today/2020.06.29-144326/https://www.nbcnews.com/health/health-news/remdesivir-coronavirus-gilead-charge-thousands-treatment-u-s-n1232385 ↩︎

  17. David R Boulware - Projects. Experts@Minnesota. Retrieved May 9, 2023, from https://experts.umn.edu/en/persons/david-r-boulware/projects/ ↩︎

  18. MSGERC Headquarters. (2018, October 25). MSGERC 2018: Cryptococcus: David Boulware. YouTube. https://web.archive.org/web/20230518194253/https://www.youtube.com/watch?v=QnQ1k4YcCWM ↩︎ ↩︎

Further reading

Who Is David Boulware?
Infectious Diseases Institute, Gilead Sciences, hydroxychloroquine, TOGETHER Trial, genetic medicine
White Rose IntelligenceLiam Sturgess